Literature DB >> 25427903

The role of iron in alcohol-mediated hepatocarcinogenesis.

Sebastian Mueller1, Vanessa Rausch.   

Abstract

Alcoholic liver disease (ALD) is the major liver disease in the developed world and characterized by hepatic iron overload in ca. 50% of all patients. This iron overload is an independent factor of disease progression, hepatocellular carcinoma and it determines survival. Since simple phlebotomy does not allow the efficient removal of excess iron in ALD, a better understanding of the underlying mechanisms is urgently needed to identify novel targeted treatment strategies. This review summarizes the present knowledge on iron overload in patients with ALD. Although multiple sides of the cellular and systemic iron homeostasis may be affected during alcohol consumption, most studies have focused on potential hepatic causes. However, it should not be overlooked that more than 90% of the major iron pool, the hemoglobin-associated iron, is efficiently recycled within the human body and it is also strongly affected by alcohol. The few available studies suggest various molecular mechanisms that involve iron regulatory protein (IRP1), transferrin receptor 1 (TfR1), and the systemic iron master switch hepcidin, but not classical mutations of the HFE gene. Notably, reactive oxygen species (ROS), namely, hydrogen peroxide (H2O2), are powerful modulators of these iron-steering proteins. For instance, depending on the level, H2O2 may both strongly suppress and induce the expression of hepcidin that could partly explain the anemia and iron overload observed in these patients. More studies with appropriate ROS models such as the novel GOX/CAT system are required to unravel the mechanisms of iron overload in ALD to consequently identify molecular-targeted therapies in the future.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25427903     DOI: 10.1007/978-3-319-09614-8_6

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  9 in total

Review 1.  Non-invasive diagnosis of alcoholic liver disease.

Authors:  Sebastian Mueller; Helmut Karl Seitz; Vanessa Rausch
Journal:  World J Gastroenterol       Date:  2014-10-28       Impact factor: 5.742

Review 2.  Iron and iron-related proteins in alcohol consumers: cellular and clinical aspects.

Authors:  Kevin Ferrao; Najma Ali; Kosha J Mehta
Journal:  J Mol Med (Berl)       Date:  2022-10-10       Impact factor: 5.606

Review 3.  Iron-Induced Hepatocarcinogenesis-Preventive Effects of Nutrients.

Authors:  Hiroyuki Tsuchiya
Journal:  Front Oncol       Date:  2022-06-27       Impact factor: 5.738

4.  Synergistic Interaction of Light Alcohol Administration in the Presence of Mild Iron Overload in a Mouse Model of Liver Injury: Involvement of Triosephosphate Isomerase Nitration and Inactivation.

Authors:  Wanxia Gao; Jie Zhao; Zhonghong Gao; Hailing Li
Journal:  PLoS One       Date:  2017-01-19       Impact factor: 3.240

Review 5.  Does Hypoxia Cause Carcinogenic Iron Accumulation in Alcoholic Liver Disease (ALD)?

Authors:  Inês Silva; Vanessa Rausch; Helmut-Karl Seitz; Sebastian Mueller
Journal:  Cancers (Basel)       Date:  2017-10-25       Impact factor: 6.639

Review 6.  Current understanding of the metabolism of micronutrients in chronic alcoholic liver disease.

Authors:  Jing Wu; Qing-Hua Meng
Journal:  World J Gastroenterol       Date:  2020-08-21       Impact factor: 5.742

7.  Novel Insights into Alcoholic Liver Disease: Iron Overload, Iron Sensing and Hemolysis.

Authors:  Sebastian Mueller; Cheng Chen; Johannes Mueller; Shijin Wang
Journal:  J Transl Int Med       Date:  2022-07-10

Review 8.  The Role of Iron and Iron Overload in Chronic Liver Disease.

Authors:  Sandra Milic; Ivana Mikolasevic; Lidija Orlic; Edita Devcic; Nada Starcevic-Cizmarevic; Davor Stimac; Miljenko Kapovic; Smiljana Ristic
Journal:  Med Sci Monit       Date:  2016-06-22

9.  Programmed cell death in alcohol-associated liver disease.

Authors:  Tatsunori Miyata; Laura E Nagy
Journal:  Clin Mol Hepatol       Date:  2020-09-21
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.